Genomic Health Announces Six New Studies Including Four Oral Presentations Covering Breast, Colon and First Study in Renal Cancer Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., May 20 /PRNewswire-FirstCall/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from six separate studies at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2010 at McCormick Place in Chicago. The studies include four oral presentations covering breast, colon and renal cancers. The company markets the widely-adopted Oncotype DXÃ‚® breast cancer test, which is clinically validated to predict chemotherapy benefit as well as the likelihood of recurrence in early-stage breast cancer patients. In addition, the company launched the Oncotype DX colon cancer test in January 2010.
The majority of ASCO Annual Meeting abstracts are now publicly available on ASCO’s website, www.asco.org.
Presentation details are as follows (all times are in Central Daylight Time):
Monday, June 7, 2010
Oral Presentation: “Recurrence risk of node-negative and ER-positive early stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta analysis approach” (Abstract #509)
- Presenter: Gong Tang, PhD, Assistant Professor, Biostatistics, University of Pittsburgh, Statistician, NSABP
- Presentation Time: 11:00 AM – 11:15 AM
- Location: N Hall B1
Oral Presentation: “Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer” (Abstract #511)
- Presenter: Kathy S. Albain, M.D., Professor, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.
- Presentation Time: 11:45 AM – 12:00 PM
- Location: N Hall B1
Poster Presentation: “The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel” (Abstract #6075)
- Lead Author: Shmuel Klang, PhD, Director, Department of Pharmacy and Pharmacology, Clalit Health Services, Tel Aviv, Israel
- Session Time: 1:00 PM – 5:00 PM
- Location: S Hall A2, Health Services Research, General Poster Session
Poster Presentation: “Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer” (Abstract #3097)
- Lead Author: Vered Stearns, MD, Associate Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine
- Session Time: 8 AM – 12:00 PM
- Location: S Hall A2, Developmental Therapeutics – Experimental Therapeutics, General Poster Session
Sunday, June 6, 2010
Oral Presentation: “Comparison of molecular and pathologic features of stage II and stage III colon cancer in 4 large studies conducted for development of the 12-gene colon cancer Recurrence Score” (Abstract#3503)
- Presenter: Michael O’Connell, MD, Professor of Human Oncology, Drexel University College of Medicine, Director of the Allegheny Cancer Center, Director of the Division of Medical Oncology at Allegheny General Hospital and Associate Chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP) in Pittsburgh, Pennsylvania
- Presentation Time: 10:30 AM – 10:45 AM
- Location: E Hall D1
Saturday, June 5, 2010
Oral Presentation: “Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC)” (Abstract # 4501)
- Presenter: Brian Rini, MD, Associate Professor of Medicine, the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio, Staff member of the Department of Solid Tumor Oncology and Associate Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute
- Presentation Time: 8:15 AM – 8:30 AM
- Location: E Hall D2
About Oncotype DXÃ‚® Breast Cancer Test
The Oncotype DX breast cancer test is the first and only multigene expression test to be recommended by both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Oncotype DX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Oncotype DX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of March 2010, more than 10,000 physicians in over 55 countries had ordered more than 148,000 tests, and both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. For more information about Oncotype DX for breast cancer, please visit www.oncotypedx.com.
About Oncotype DXÃ‚® Colon Cancer Test
The Oncotype DX colon cancer test is the first multigene expression test commercially available that has been clinically validated to predict risk of recurrence in patients with stage II colon cancer. For its colon cancer program, Genomic Health and its collaborators used the same rigorous clinical development strategy and standardized quantitative technology designed for the company’s Oncotype DX breast cancer test. National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted three development studies and Cleveland Clinic conducted one development study, all of which were funded by Genomic Health, analyzing 761 genes from 1,851 patients with stage II colon cancer. The final set of seven recurrence and five reference genes were then independently evaluated in 1,436 stage II colon cancer patients in the QUASAR validation study. Availability of the test in New York is pending review by the state, as is required for all laboratory developed tests. For more information about Oncotype DX for colon cancer, please visit www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DXÃ‚® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health